Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezetimibe/rosuvastatin + telmisartan - Hanlim Pharm

Next Previous
Drug Profile

Ezetimibe/rosuvastatin + telmisartan - Hanlim Pharm

Latest Information Update: 01 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Azetidines; Benzimidazoles; Benzoates; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hypertension

Most Recent Events

  • 01 Feb 2023 Phase-III development in Hypertension is ongoing in South Korea (PO)
  • 01 Feb 2023 Phase-III development in Hypercholesterolaemia is ongoing in South Korea (PO)
  • 02 Jun 2021 Navipharm plans a phase I trial in Healthy volunteers in South Korea (PO) in August 2021 (NCT04905342)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top